Posted in | News | Nanomedicine

Scientists Develop New Nanoparticle for Intravenous Cancer Immunotherapy

Cancer immunotherapy aims to change “cold” tumors into “hot” tumors – those that react to immunotherapy – by stimulating and enlisting the immune system of the body.

Scientists Develop New Nanoparticle for Intravenous Cancer Immunotherapy.

Image Credit: Photos

Regrettably, few people gain from the most frequently used form of immunotherapy, known as immune checkpoint inhibitors, and researchers are keenly seeking new and harmless molecules called agonists to boost the immune response of the body. The STING agonist is one potential drug in clinical trials. STING is a protein critical to the immune response against contagion as well as cancer.

In hunting for molecules that would boost the STING pathway, researchers at the University of Michigan’s College of Pharmacy and the Rogel Cancer Center chose nutritional metal ions, which humans absorb from food and are vital for immune regulation.

They learned that incorporating the nutritional metal ion manganese to STING agonists enhanced STING’s capability to fight tumors by nearly 77-fold, compared to STING agonists used in isolation, said James Moon, the J.G. Searle Professor of Pharmaceutical Sciences and professor of biomedical engineering.

When scientists incorporated the manganese ions into STING agonists, they created nano-sized crystals, which considerably boosted cellular uptake of STING agonists and STING activation by immune cells. To develop a STING agonist for intravenous administration, the team coated these nanocrystals with a lipid layer (akin to those used in mRNA COVID19 vaccines), resulting in a nanoparticle system referred to as CMP.

The majority of STING agonists must be transported directly into the tumor, but this is not ideal for metastatic cancers - the main cause of mortality. Even with intratumoral injections, present-day STING agonists are faced with partial clinical response.

CMP significantly increases cellular uptake of STING agonists, and together with manganese, CMP triggers robust STING activation, turns a cold tumor into hot tumor, and eliminates cancer, including those that are completely resistant to immune checkpoint inhibitors, the most widely used cancer immunotherapy.

Xiaoqi “Kevin” Sun, Study First Author and Graduate Student in Pharmacy, University of Michigan

Moon explained that this was the first time that nanoparticles transporting STING agonists and metal ions have been engineered for intravenous cancer immunotherapy, and this could pave the way for cancer immunotherapy treatments.

The team showed the tumor-combating effects of CMP in different tumors, including melanoma, colon carcinoma and head and neck cancer.

A majority of neck and head cancers do not react well to immune checkpoint inhibitors. To model this fatal disease, the team designed a head and neck cancer model that was totally resistant to immune checkpoint inhibitors, said study senior co-author Yu Leo Lei, U-M associate professor of dentistry. The model, called NOOC1, has more than 90% similarity in mutational signatures to smoking-related human cancers.

In the head and neck cancer tumor, CMP administered intravenously eradicated those tumors in 75% of mice. In contrast, conventional STING agonists had minimal anti-tumor effects and all animals succumbed to tumor growth.

Yu Leo Lei, Study Senior Co-Author and Associate Professor of Dentistry, University of Michigan

The study team is at present looking to test the safety and effectiveness of CMP in large animals.

We anticipate that we will be able to initiate a phase I clinical study to examine the efficacy of CMP in cancer patients in the near future.

James Moon, The J.G. Searle Professor of Pharmaceutical Sciences and Professor of Biomedical Engineering, University of Michigan

The research has been published in the September 30th online issue of Nature Nanotechnology.

Journal Reference:

Sun, X., et al. (2021) Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nature Nanotechnology.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.